Nerva, the world’s leading digital therapeutic for Irritable Bowel Syndrome (IBS), announces that it has acquired key assets of Mahana Therapeutics, a pioneer in digital therapies for chronic conditions, including IBS. Backed by over $80 million in venture funding, Mahana was foundational in establishing prescription digital therapeutics for digestive health. This strategic acquisition strengthens Nerva’s leadership in app-based brain-gut therapy and will accelerate its mission to deliver evidence-based, accessible care to the millions of patients living with IBS.
Read the full article: Nerva Completes Mahana Therapeutics Acquisition to Expand Access to Digital Therapies for IBS //
Source: https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/nerva-completes-mahana-therapeutics-acquisition-to-expand-access-to-d-1023939